[Genomic signature of breast cancer: The quest for the Holy Grail].
The role of molecular signatures in the adjuvant management of breast cancer remains a debated topic. Discussions should take into account the level of scientific validation, the impact on practice, the expected benefits and financing issues. This article presents the limits to be clarified before using commercial molecular signatures.